Company Overview and News

2
20 Gambling Stocks to Play the Booming Economy

14h investorplace
The gambling sector has performed exceedingly well of late. Domestic gambling stocks have soared, thanks to reduced debt and improved margins. As a result, those stocks are receiving multiples not seen since before the financial crisis.

 
3 Casino Stocks to Buy Now

14h investorplace
Perhaps it is because trading stocks can often mirror the thrill of winning big at the blackjack tables, or maybe it is because Las Vegas conjures images of the world’s most flashy brands and businessmen. Regardless of the reason, it is clear that gambling stocks are always among the most popular on Wall Street.

 
Tiffany (TIF) Tops Q1 Earnings & Sales, Ups FY18 Outlook

2018-05-23 zacks
Tiffany & Co. (TIF - Free Report) , the designer and retailer of fine jewelry, came out with first-quarter fiscal 2018 results, wherein earnings of $1.14 per share beat the Zacks Consensus Estimate of 84 cents and increased more than 50% year over year. Earnings Estimate Revision: The Zacks Consensus Estimate for fiscal 2018 remained stable in the last 30 days. In the trailing four quarters (excluding the quarter under review), the company outperformed the Zacks Consensus Estimate by an average of 4.

 
Moving Average Crossover Alert: LogMein, Inc. (LOGM)

2018-05-23 zacks
LogMein, Inc. (LOGM - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for LOGM broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

 
Moving Average Crossover Alert: Federated Investors, Inc. (FII)

2018-05-23 zacks
Federated Investors, Inc. (FII - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for FII broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

 
Moving Average Crossover Alert: Flotek Industries, Inc. (FTK)

2018-05-23 zacks
Flotek Industries, Inc. (FTK - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for FTK broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

 
5 Reasons Why You Should Add RLI Stock to Your Portfolio

2018-05-22 zacks
Estimates for RLI Corp. (RLI - Free Report) have been revised upward over the past seven days, instilling analysts’ confidence in the stock post solid first-quarter earnings results. The stock has seen the Zacks Consensus Estimate for current-year earnings being raised 0.9% to $2.25. RLI Corp. underwrites property and casualty insurance in the United States and internationally. The company boasts an enviable profile, emerging strong as one of the industry’s most profitable P&C writers with an impressive track record of underwriting profits in 37 of the past 41years, particularly the last 22 years.

 
Kirkland's Cheer Store & E-commerce Growth, High Costs a Woe

2018-05-22 zacks
Kirkland's, Inc. (KIRK - Free Report) well-knit strategic endeavors to boost sales have been yielding positively, evident from consistent year-over-year improvement in top line for almost nine straight quarters. The company has been gaining from its efforts to enhance merchandise assortments, develop e-commerce business and constant store additions.

 
Las Vegas Sands (LVS) Outruns Peers, Surges 38% in a Year

2018-05-22 zacks
Las Vegas Sands Corp. (LVS - Free Report) has done exceedingly well and emerged as an attractive investment option amid an intensely competitive gaming industry. This is evident from the company’s performance in a year’s time. While the stock has surged 37.8%, the industry rallied 26.4%.

 
MSG Sphere: 7 Things to Know About New Arena Coming to Las Vegas Strip

2018-05-21 investorplace
MSG Sphere is the latest development in music technology as it will consist of a new arena in the Las Vegas strip with remarkable acoustics.

 
Everything Investors Need to Know About Legal Sports Gambling

2018-05-21 zacks
Welcome to the latest episode of the Full-Court Finance podcast from Zacks Investment Research. On this week’s episode, Ben Rains breaks down everything investors need to know about the future of the legal sports gambling industry after the U.S. Supreme Court’s historic ruling.

 
U.S. Supreme Court Allows Sports Betting: Now What For Investors?

2018-05-18 seekingalpha
The landmark court decision unleashes what could be a $150 billion industry within the next five years.

 
Is Las Vegas Sands (LVS) Outperforming Other Consumer Discretionary Stocks This Year?

2018-05-17 zacks
Investors focused on the Consumer Discretionary space have likely heard of Las Vegas Sands (LVS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LVS and the rest of the Consumer Discretionary group's stocks.

 
EPA’s Pruitt Faces First Senate Grilling Since Ethics Allegations - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Zacks Investment Ideas feature highlights: Wynn Resorts, Las Vegas Sands, Caesar???s Entertainment, Penn National Gaming and International Game Technology

2018-05-16 zacks
Chicago, IL – May 16, 2018 – Today, Zacks Investment Ideas feature highlights Features: Wynn Resorts (WYNN - Free Report) , Las Vegas Sands (LVS - Free Report) , Caesar’s Entertainment Corp (CZR - Free Report) , Penn National Gaming (PENN) and International Game Technology (IGT - Free Report) .

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 517834107